^
    1d
    SCAR: Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, Zhejiang University | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    capecitabine • oxaliplatin • Hetronifly (serplulimab) • celecoxib oral
    1d
    A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) (clinicaltrials.gov)
    P3, N=541, Active, not recruiting, DualityBio Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • mTOR (Mechanistic target of rapamycin kinase)
    |
    HER-2 positive • HER-2 expression • HER-2 underexpression
    |
    capecitabine • albumin-bound paclitaxel • trastuzumab pamirtecan (BNT323)
    2d
    Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, Sun Yat-sen University
    New P2 trial • pMMR
    |
    capecitabine • oxaliplatin • Puyouheng (pucotenlimab)
    2d
    Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC (clinicaltrials.gov)
    P2, N=128, Not yet recruiting, Hebei Medical University Fourth Hospital
    New P2 trial • pMMR
    |
    capecitabine • oxaliplatin • Enshuxing (enlonstobart)
    2d
    A Clinical Study Based on FAPI-PET/CT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal Cancer (clinicaltrials.gov)
    P2, N=52, Completed, Sun Yat-sen University | Recruiting --> Completed | Trial primary completion date: Dec 2025 --> Jul 2025
    Trial completion • Trial primary completion date
    |
    Tyvyt (sintilimab) • capecitabine • oxaliplatin
    2d
    ARTEMIDE-Bil01: Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) (clinicaltrials.gov)
    P3, N=757, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cisplatin • gemcitabine • capecitabine • Teysuno (gimeracil/oteracil/tegafur) • rilvegostomig (AZD2936)
    2d
    CIME/ET23-185: Study aiming to compare the survival of patients with locally advanced or metastatic MSI/dMMR Esogastric adenocarcinomas treated by a combination of Immune checkpoint inhibitors (botensilimab + balstilimab) versus the standard of care (FOLFOX/XELOX + nivolumab) (2023-506291-28-00)
    P2/3, N=132, Recruiting, Centre Leon Berard | Not yet recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition • dMMR
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR • HER-2 negative
    |
    Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • balstilimab (AGEN2034) • botensilimab (AGEN1181)
    2d
    LUCERNA: A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (clinicaltrials.gov)
    P3, N=500, Recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Dec 2029 --> Sep 2028 | Trial primary completion date: Dec 2029 --> Sep 2028
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • CLDN18 (Claudin 18)
    |
    MSI-H/dMMR • HER-2 negative
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • Vyloy (zolbetuximab-clzb)
    3d
    A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P3, N=422, Not yet recruiting, Akeso
    New P3 trial
    |
    capecitabine • oxaliplatin • Kaitanni (cadonilimab)
    3d
    SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases (clinicaltrials.gov)
    P2, N=42, Recruiting, Fujian Cancer Hospital | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Dec 2027 --> Dec 2026 | Not yet recruiting --> Recruiting
    Enrollment open • Trial completion date • Trial primary completion date
    |
    capecitabine • oxaliplatin • Qibeian (iparomlimab/tuvonralimab)
    3d
    A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer (clinicaltrials.gov)
    P2, N=70, Not yet recruiting, Jiangsu Cancer Institute & Hospital
    New P2 trial
    |
    MSI (Microsatellite instability)
    |
    Avastin (bevacizumab) • capecitabine • oxaliplatin • irinotecan • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    7d
    Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study. (PubMed, Breast Cancer Res Treat)
    Outcomes after CDK4/6i progression differ by PAM50 IS, supporting its role in guiding post-progression treatment.
    Journal • Real-world evidence • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PD-1 (Programmed cell death 1) • CCNE1 (Cyclin E1)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    |
    capecitabine